Ask AI
Individualizing 2L+ CLL Therapy

CME

Individualizing CLL Therapy: Second-Line Treatment and Beyond

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 16, 2024

Expiration: August 15, 2025

Activity

Progress
1
Course Completed

Introduction

In this activity, Jeremy S. Abramson, MD, MMSc; Farrukh Awan, MD; and Shuo Ma, MD, PhD, discuss factors in treatment decision-making for patients with chronic lymphocytic leukemia (CLL) who require second- or later-line therapy.  

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

How many people with CLL do you provide care for in a typical month?

In your current practice, what would you recommend for this patient?

In your current practice, which of the following would you recommend for this patient?